Uttam Rao
Hematology & Oncology · Austin, TXNPI 1821476011
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,498 of the $37,291 with a category attached, or 65.7%. E.r. Squibb & Sons, L.L.C. accounts for 81.6% of it on its own, with 13 other manufacturers making up the rest.
Across 84 payments — averaging $443.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$30K
- National Marrow Donor Program$3K
- Janssen Scientific Affairs, LLC$2K
- Bristol Myers Squibb$1K
- Sanofi-aventis U.S. LLC$206
- Legend Biotech USA Inc.$200
- plus $758 from 8 others
Across 34 payments — averaging $10,037 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- National Marrow Donor Program$341K
What the payments were for
- Consulting fees$2,9738%
- Speaking & faculty fees$24,49866%
- Travel & lodging$7,35120%
- Food & beverage$2,4377%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 21 | $30,446 |
| National Marrow Donor Program | 9 | $2,556 |
| Janssen Scientific Affairs, LLC | 7 | $2,049 |
| Bristol Myers Squibb | 15 | $1,076 |
| Sanofi-aventis U.S. LLC | 3 | $206 |
| Legend Biotech USA Inc. | 6 | $200 |
| Johnson & Johnson | 12 | $150 |
| Jazz Pharmaceuticals Inc. | 1 | $131 |
| Novartis | 4 | $124 |
| Astellas Pharma US Inc | 1 | $124 |
| Gilead(2 entities) | 2 | $119 |
| AstraZeneca | 1 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Daiichi Sankyo Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,291 in reported general payments places this provider in the 85th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 34 | $1,782 |
| Potassium Chloride | 12 | $100 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Austin
- Michael LattanziAustin$222K
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.